Silence Therapeutics (NASDAQ:SLN) Given New $45.00 Price Target at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its target price lowered by stock analysts at Morgan Stanley from $49.00 to $45.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock.

SLN has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group reduced their price objective on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating on the stock in a research report on Tuesday. BMO Capital Markets lowered their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $4.38 on Wednesday. Silence Therapeutics has a one year low of $4.06 and a one year high of $27.72. The business has a 50 day simple moving average of $5.53 and a 200 day simple moving average of $11.58. The stock has a market capitalization of $130.94 million, a P/E ratio of -2.79 and a beta of 1.05.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new stake in Silence Therapeutics during the fourth quarter worth about $26,000. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 609.2% in the fourth quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock valued at $42,000 after purchasing an additional 5,233 shares during the last quarter. Barclays PLC increased its position in shares of Silence Therapeutics by 83.8% in the fourth quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after buying an additional 2,793 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics during the 4th quarter valued at about $69,000. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of Silence Therapeutics by 130.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after purchasing an additional 6,098 shares in the last quarter. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.